

Total Synthesis of Cystothiazoles
A and B


Jian Shao and James S. Panek*

Department of Chemistry and Center for Chemical Methodology and
Library Development, Boston University, 590 Commonwealth Avenue,
Boston, Massachusetts 02215

panek@chem.bu.edu

Received June 11, 2004


ABSTRACT



Convergent enantioselective syntheses of the antifungal agents cystothiazoles A and B are described. The routes feature an asymmetric crotylation using a propargylic dicobalt hexacarbonyl complex, which provided enhanced diastereoselectivity over the uncomplexed propargylic acetal. The bisthiazole fragment was united with the side chain through a Stille cross-coupling of a terminal (*E*)-vinylstannane with a 4-triflyl-substituted thiazole.

In 1998, Sakagami and co-workers reported the isolation of cystothiazoles A and B from a culture broth of the myxobacterium, *Cystobacter fuscus*.¹ Cystothiazoles A and B have demonstrated potent antifungal activity against a wide range of fungi. These agents, however, show little or no effect on inhibition of bacterial growth. Although these compounds are structurally related to the known antibiotic myxothiazole,² cystothiazole A is more active against fungi and less cytotoxic.

Earlier reports have documented the independent total synthesis of cystothiazoles A, B, C, E and G.³ In this paper, we describe convergent enantioselective syntheses of cystothiazoles A and B.



Our retrosynthetic strategy is illustrated in Scheme 1. The target molecules could be divided into two subunits, C₁–C₇ fragment 4 and bisthiazole fragment 5, which will be coupled at a late stage via a Stille cross-coupling reaction. The C₁–C₇ fragment could be obtained from the β -ketoester 6, which was ultimately derived from a crotylsilane addition to the dicobalt hexacarbonyl complex 10. The bisthiazole fragment 5 was synthesized by a regioselective Stille cross-coupling reaction with the 2,4-bis(triflyl) thiazole 7 and 4-bromothiazole 8.⁴

In our preliminary studies, it was found that the direct crotylation between silane (*S*)-9 and the 3-(trimethylsilyl)


(1) (a) Ojika, M.; Suzuki, Y.; Tsukamoto, A.; Sakagami, Y.; Fudou, R.; Yoshimura, T.; Yamanaka, S. *J. Antibiot.* **1998**, 51, 275–281. (b) Suzuki, Y.; Ojika, M.; Sakagami, Y.; Fudou, R.; Yamanaka, S. *Tetrahedron* **1998**, 54, 11399–11404.

(2) (a) Gerth, K.; Irschik, H.; Reichenbach, H.; Trowitzsch, W. *J. Antibiot.* **1980**, 33, 1474–1479. (b) Trowitzsch, W.; Reifensahl, G.; Wray, W.; Gerth, K. *J. Antibiot.* **1980**, 33, 1480–1490.

(3) (a) Williams, D.; Patnaik, S.; Clark, M. *J. Org. Chem.* **2001**, 66, 8463–8469. (b) Kato, K.; Nishimura, A.; Yamamoto, Y.; Akita, H. *Tetrahedron Lett.* **2002**, 43, 643–645. (c) Kato, K.; Sasaki, T.; Takayama H.; Akita, H. *Tetrahedron* **2003**, 59, 2679–2685. (d) DeRoy, P.; Charette, A. *Org. Lett.* **2003**, 5, 4163–4165. (e) Bach, T.; Heuser, S. *Angew. Chem., Int. Ed.* **2001**, 40, 3184–3185. (f) Sasaki, T.; Kato, K.; Akita, H. *Chem. Pharm. Bull.* **2004**, 52, 770–771. (g) Akita, H.; Sasaki, T.; Kato, K.; Suzuki, Y.; Kondo, K.; Sakagami, Y.; Ojika, M.; Fudou, R.; Yamanaka, S. *Tetrahedron* **2004**, 60, 4735–4738.


(4) Langille, N. F.; Dakin, L. A.; Panek, J. S. *Org. Lett.* **2002**, 4, 2485–2488.

Scheme 1. Retrosynthesis



propargyl dimethyl acetal **11** produced the homoallylic ether in high yield (> 80%); however, it did so without useful selectivity (syn/anti = 2:1). To get around this problem, a propargylic dicobalt complex⁵ was used to add steric bulk to the acetal, which we hoped would create a sufficient energy difference between the competing diastereotopic transition states during the crotylation. Gratifyingly, reaction of silane (*S*)-**9** with the cobalt complexed acetal **10** resulted in a significant enhancement of diastereoselectivity (syn/anti > 10:1), affording the homoallylic ether in 86% yield (Scheme 2).⁶ The removal of the dicobalt complex of **13**

Scheme 2




was achieved using trimethylamine *N*-oxide in MeOH. The cleavage of the olefin by ozonolysis gave the aldehyde **14** in 68% yield, which is volatile and prone to decomposition at room temperature. This material was submitted to low-temperature condensation with the lithium enolate derived

from methyl acetate. The resulting mixture of diastereomeric alcohols **15** was subjected to an oxidation using PCC to form the β -ketoester **6** in 85% yield (6:1 ketone/enol form determined by ¹H NMR). β -Ketoester **6** was treated with trimethyl orthoformate in the presence of catalytic sulfuric acid to form the desired (*E*)- β -methoxyacrylate **16** in 86% yield (*E*:*Z* = 7:1 as determined by ¹H NMR).⁷ The *E* geometry was assigned by measurement of NOE for the olefin proton and the methoxy group. After deprotection by K₂CO₃ in methanol, the alkyne **17** was subjected to the Pd-catalyzed hydrostannylation. β -(*E*) regioselective product **4** was achieved in 84% yield (α : β -(*E*): β -(*Z*) = 1:7:0 as determined by ¹H NMR relative to the MeO group).⁸

The bisthiazole fragments **5a** and **5b** were derived from three different thiazoles as illustrated in Schemes 4 and 5.

Scheme 3



Accordingly, 4-bromo-2-isopropyl-thiazole **8a** was obtained by a regioselective Negishi cross-coupling reaction from the dibromide **18**⁹ in 72% yield.¹⁰ As predicted, the reaction occurred at the most electron-deficient position of the heterocycle. The synthesis of the 4-bromo-2-(isopropyl-*tert*-butyldimethylsilyloxy)-thiazole **8b** involved a bromine–lithium exchange, followed by the addition of anhydrous acetone, followed by treatment of the derived secondary

(5) (a) Schreiber, S. L.; Klimas, M. T.; Sammakia, T. *J. Am. Chem. Soc.* **1987**, *109*, 5749–5759. (b) Jamison, T. F.; Shambayati, S.; Crowe, W. E.; Schreiber, S. L. *J. Am. Chem. Soc.* **1997**, *119*, 4353–4363.

(6) Sui, M.; Panek, J. S. *Org. Lett.* **2001**, *3*, 2439–2442.


(7) Poirier, J. M.; Hennequin, L. *Tetrahedron* **1989**, *45*, 4191–4202.

(8) Smith, A. B.; Ott, G. R. *J. Am. Chem. Soc.* **1998**, *120*, 3935–3948.


(9) Reynaud, P.; Robba, M.; Moreau, R. C. *Bull. Soc. Chim. Fr.* **1962**, 1735–1738.

(10) Bach, T.; Heuser, S. *J. Org. Chem.* **2002**, *67*, 5789–5795.

Scheme 4



Scheme 5



alcohol with TBSOTf and 2,6-lutidine, and gave the silyl-protected bromothiazole **8b** in 98% yield.

The bisthiazole fragments of **1** and **2** were formed through Stille cross-coupling reactions. The required 4-tributylstannylthiazoles **19a** and **19b** were prepared from the bromide by bromine–lithium exchange and the subsequent quench

with Bu_3SnCl . The crude stannane was submitted directly to the Stille cross-coupling reaction with the ditriflate **7** using $\text{Pd}(\text{PPh}_3)_4$ as a catalyst, dioxane as a solvent, and the addition 3 equiv of LiCl . The reactions were achieved in 72 and 68% yields when $\text{R} = \text{H}$ or OTBS , respectively.^{4,11} Identical conditions were employed for the construction of the bisthiazole fragments in the final Stille cross-coupling reaction. Cystothiazole A (**1**) could be synthesized directly from the coupling of the C_1 – C_7 fragment **4** and bisthiazole fragment **5a** in 85% yield. After the Stille cross-coupling of the C_1 – C_7 fragment **4** and bisthiazole fragment **5b** (72% yield), a final deprotection step using TBAF gave cystothiazole B (**2**) in 98% yield.

In summary, convergent enantioselective syntheses of the antifungal agents cystothiazoles A and B have been achieved. Cystothiazole A was synthesized in 12 linear steps and 15% overall yield, and cystothiazole B was synthesized in 13 linear steps and 13% overall yield. Key features of the synthesis include high levels of selectivity in the crotylation using a propargylic dicobalt hexacarbonyl complex to establish the syn-homoallylic ether of the side chain. The bisthiazole fragment was coupled to the left-hand side chain using a Stille cross-coupling. On balance, the asymmetric crotylation methodology, together with transition metal-mediated cross-coupling reaction, offers a promising and efficient approach to these natural products.

Acknowledgment. We acknowledge Professor Sakagami and Professor Ojika (Nagoya University) for authentic samples of cystothiazoles A and B. We thank Mr. Qibin Su and Neil Langille (Boston University) for helpful discussions. Financial support was obtained from the NIH-GM55740. J.S.P. is grateful to Johnson & Johnson, Merck Co., Amgen, Inc., Novartis, Pfizer, and GSK for financial support.

Supporting Information Available: General experimental procedures, including spectroscopic and analytical data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL048893D

(11) Arcadi, A.; Attanasi, O. A.; Guidi, B.; Rossi, E.; Santeusano, S. *Eur. J. Org. Chem.* **1999**, 3117–3126.